FDA Approves First-Ever RSV Vaccine for Older Adults

The U.S. Food and Drug Administration in White Oak, Md., on July 20, 2020. Sarah Silbiger/Getty Images

The U.S. Food and Drug Administration (FDA) approved the first-ever respiratory syncytial virus (RSV) vaccine for use in adults aged 60 and over on Wednesday.

The approval of its drug Arexvy is a major victory for British pharmaceutical giant GlaxoSmithKline (GSK), which has been rushing to get its RSV vaccine out to the market before competitors including Pfizer, Johnson & Johnson, and Moderna.